MYC and colorectal carcinoma: In this study, we sought to evaluate the use of p38α and c-MYC protein expression as biomarkers to select a specific subpopulation of CRC patients that can achieve adequate clinical benefit through p38α pharmacological inhibition by ralimetinib.